Benitec Biopharma Ltd ADR BNTC

$9.04 -0.05 (-0.55%)

Valuation

Market cap
317,141,000
Revenue TTM
$0
Net income TTM
$-45,550,000
P/E (trailing)
0.00
P/E (forward)
—
Profit margin
0.00%
Debt to equity
0.00

Trading

Volume
144,600
Avg volume
185,574
Day's range
$8.69 – $9.36
Shares out
34,889,000
Stochastic %K
38%
Beta
0.26
Analysts
Strong Buy
Price target
$23.29

Price

Company profile

Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines in the United States. Its Silence and Replace, a DNA-directedRNA interference platform, that combines RNA interference with gene therapy to create medicines which simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a s...

Show more

Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines in the United States. Its Silence and Replace, a DNA-directedRNA interference platform, that combines RNA interference with gene therapy to create medicines which simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The company is developing BB-301, an AAV-based gene therapy designed to silence the expression of the disease-causing gene, which is in phase 1b/2a for the treatment of oculopharyngeal muscular dystrophy related dysphagia. Benitec Biopharma Inc. is headquartered in Hayward, California.

Industry
Biotechnology
Sector
Healthcare
Phone
510 780 0819
Website
https://benitec.com
Address
3940 Trust Way, Hayward, United States

Latest news

Stocktwits

Ian_FV Nov 13, 2:56 PM
6-K/8-K Important Update $BNTC Benitec Biopharma Inc. reported first-quarter fiscal 2027 financial results, with total expenses rising to $14.5 million from $9.8 million in the same period in 2025, driven by increased research and development costs. The company has changed its fiscal year-end to December 31, starting January 1, 2027, to improve result comparability. Positive interim results from the BB-301 Phase 1b/2a study showed a 100% responder rate with no serious adverse events, and the company plans to begin a pivotal trial in mid-2027. As of September 30, 2026, Benitec held approximately $176 million in cash and cash equivalents. More details at www.ianfv.com
0 replies
focafoca99 Nov 13, 1:11 PM
$BNTC approved a fiscal year change to calendar year reporting, effective Nov 12.
0 replies
Rayvio_News_Filter Nov 13, 1:02 PM
$BNTC 🏥 Benitec Biopharma Inc. reported positive interim clinical results from the ongoing BB-301 Phase 1b/2a study, showing a 100% responder rate across Cohort 1 and Cohort 2 in dysphagic patients with Oculopharyngeal Muscular Dystrophy. Actionable market event
0 replies
GTA_Terminal Nov 9, 12:36 PM
Unusual options activity in $BNTC. Money on both sides, which usually means traders expect a move but don't agree on the direction. Read the full article for the full details: https://globaltradersacademy.com/articles/bntc-technical-levels-options-flow-mixed-between-8-70-and-9-56?utm_source=stocktwits&utm_medium=social
0 replies
MisterRagnirLothbrok Nov 5, 12:27 AM
Ticker SCAG had huge news today: Scage Future Enters into Strategic Cooperation Agreement with China Huaye Group SCAG has only 1.3 million shares float - Chinese - Watch it 👀🚀 $AGIG $TPET $TPST $BNTC @
0 replies
buymoremakemore Oct 28, 5:46 PM
$BNTC Good data. This is getting FDA approval and bought out.
0 replies
focafoca99 Oct 28, 12:13 PM
$BNTC discloses positive interim Phase 1b/2a data for BB-301, showing high-dose efficacy and durable low-dose improvements.
0 replies
Rayvio_News_Filter Oct 28, 12:05 PM
$BNTC 🏥 Benitec Biopharma Inc. reported positive interim Phase 1b/2a results for high-dose BB-301 and continued durable improvements for low-dose BB-301, with 100% of treated OPMD patients across both doses being formal responders.
0 replies